AUTHORS
Joseph T Kannarkat, MD, Khuthadzo Hlongwane2, Garrick Laudin3, Andrew H Karaba, MD4, Kennedy Otwombe, PhD5, Andrea L Cox, MD6, Atul Lakha7, Neil A Martinson8, Samantha L Vogt, MD, MPH9
AFFILIATIONS
1 Johns Hopkins School of Medicine, Baltimore, Maryland, United States
2 University of the Witwatersrand, Johannesburg, South Africa
3 Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa
4 Johns Hopkins School of Medicine, Baltimore, Maryland, United States
5 University of the Witwatersrand, Johannesburg, South Africa, University of the Witwatersrand, Johannesburg, South Africa
6 Johns Hopkins School of Medicine, Baltimore, Maryland, United States
7 Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa
8 Johns Hopkins School of Medicine, Baltimore, Maryland, United States, University of the Witwatersrand, Johannesburg, South Africa
9 Johns Hopkins School of Medicine, Baltimore, Maryland, United States, University of the Witwatersrand, Johannesburg, South Africa
ABSTRACT
Introduction: HIV is associated with an increased risk of lymphoma, including Hodgkin lymphoma (HL). Although treatment outcomes for HIV-associated HL have improved, real-world survival remains worse for people with HIV (PWH), particularly in low- and middle-income countries (LMICs). Delayed diagnosis, advanced-stage disease, and inflammatory syndromes such as hemophagocytic lymphohistiocytosis (HLH) may contribute to poor outcomes. Thymus and activation-related chemokine (TARC; CCL17) is a recognized biomarker for HL in people without HIV but has not been well characterized in PWH. The Optimized HLH Inflammatory (OHI) index was developed to improve diagnosis and prognostication of HLH-spectrum inflammation in adults with hematologic malignancies. We evaluated whether elevated TARC, ferritin and soluble IL-2 receptor (sIL-2R) levels, as biomarkers and components of an inflammatory index, are associated with HL in PWH.
Methods: We conducted a prospective case-control study of HIV-positive adults with HL, aggressive non-Hodgkin lymphoma (NHL) or disseminated tuberculosis (TB) in Johannesburg, South Africa. Disseminated TB was included as a comparator because of its clinical overlap with HL in HIV-positive patients. Eligible participants were aged ≥18 years with documented HIV infection. Lymphoma diagnoses were pathologically confirmed and disseminated TB diagnoses were based on a positive urine lipoarabinomannan test. Blood was collected at enrollment and processed locally. Ferritin and sIL-2R were measured locally, and plasma samples were shipped to Baltimore for TARC analysis using a custom multiplex kit (Meso Scale Diagnostics, Rockville, MD). An H-score was calculated using clinically available data, and patients were classified as OHI-positive if both sIL-2R exceeded 3,900 U/mL and serum ferritin exceeded 1,000 ng/mL. Categorical variables were compared using chi-square tests and continuous variables using the Kruskal-Wallis test.
Results: Between April 2025 and February 2026, 72 patients with HIV were enrolled, including 16 with HL, 17 with NHL and 39 with disseminated TB. Three patients were excluded from the analysis: two with HL (one with non-classical HL and one with missing sIL-2R) and one with low-grade NHL. The median age was 42 years (IQR 35–50), and 45% (31/69) were male. Overall, 61% had detectable HIV viral load, and the median CD4 count was 110 cells/mm³ (IQR 47–222). Demographic characteristics and markers of HIV control were similar across groups. Seventy-one percent of patients with HL (10/14) had stage IV disease, including eight patients with bone marrow involvement. By comparison, 56% of patients with NHL had stage IV disease, but only one had bone marrow involvement (p=0.0112). Median TARC was highest in HL (1320 pg/mL; IQR 348 – 5842) compared with NHL (100 pg/mL; IQR 53 – 397; p=0.0010) and TB (160 pg/mL; IQR 85 – 349; p=0.0005). Median ferritin was also highest in HL (1324 ng/mL; IQR 637–5368) compared with NHL (249 ng/mL; IQR 21–400; p=0.0008) and TB (500 ng/mL; IQR 208–1132; p=0.0188). Median sIL-2R was highest in HL (4938 U/mL; IQR 2883–7500) compared with NHL (962 U/mL; IQR 593–2048; p=0.0001) and TB (1038 U/mL; IQR 635–1549; p<0.0001). Among the nine OHI-positive patients, seven had lymphoma and all seven had HL. OHI-positive patients had lower white blood cell counts, hemoglobin, platelets, and albumin, and a significantly higher H-score than OHI-negative patients (132 vs 37; p<0.0001).
Conclusion: HIV-associated HL shows a distinct hyperinflammatory biomarker profile, with elevated TARC, ferritin, and sIL-2R distinguishing it from disseminated TB and NHL. OHI positivity was strongly associated with HL and with cytopenias and high H-scores, suggesting severe HLH-spectrum inflammation. These findings support further validation of inflammatory biomarkers as clinically relevant tools in HIV-associated HL.
DISCLOSURES
Samantha L Vogt, MD, MPH: Bristol Myers Squibb - Consultancy (Includes expert testimony)